Endosense, a Geneva, Switzerland-based a medical technology company focused developing technology for catheter ablation for the treatment of cardiac arrhythmias, has raised $40.3m in Series C funding.
The round was led by new investor NGN Capital, with participation from existing investors Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie, as well as multiple employees.
Founded in 2003 and led by Jan Keltjens, president, and CEO and Chairman, Endosense focuses on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company developed the use of contact-force measurement in catheter ablation with the development of the TactiCath, a force-sensing ablation catheter designed to give physicians a real-time measure of contact force during the catheter ablation procedure.
Endosense intends to use the capital to create a new direct sales organization in Europe, commercialize the recently introduced third-generation TactiCath Quartz force-sensing catheter, develop products, complete the TOCCASTAR investigational device exemption (IDE) clinical study follow-up and FDA approval submission for the TactiCath; and, launch of the device in the United States.
In conjunction with the financing, NGN Capital Managing General Partner Peter Johann, Ph.D. has joined the company’s board of directors.